TY - JOUR
T1 - Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy
T2 - Internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death
AU - Epstein-Barash, Hila
AU - Gutman, Dikla
AU - Markovsky, Ela
AU - Mishan-Eisenberg, Galit
AU - Koroukhov, Nickolay
AU - Szebeni, Janos
AU - Golomb, Gershon
PY - 2010/9
Y1 - 2010/9
N2 - Partial inactivation and transient depletion of monocytes/macrophages by liposomal bisphosphonates (LIP-BPs) is widely experimented in various inflammatory disorders including restenosis. Previous studies on activation of cytokines by LIP-BPs are limited to certain cell lines. Moreover, the correlation between in vitro and in vivo studies and complement (C) activation has not been reported. We report here a comprehensive study on the bioactivity of LIP-BPs on various cells' internalization and proliferation, mechanism of cell death, cytokines (in vitro and in vivo) and C activation (in the rat, rabbit and pig). The role of the following parameters has been determined i) drug type (clodronate/alendronate); ii) vesicles size (60-800. nm); iii) charge (neutral/negative/ positive); and iv) cell culture type (various cell lines and primary cultures). It was found that monocyte/macrophage inhibition and cytokine activation depend on the cell type, with a limited correlation to the bioactivity obtained in the rat and rabbit models of restenosis. Negatively charged liposomes (85 ± 20 nm) effectively depleted rabbit's monocytes (67% depletion), with a minor activation of cytokines and no C activation. It is concluded that cell culture studies are insufficient for assessing cytokine activation, and that by controlling LIP-BP properties (size, charge and drug type) optimal bioactivity could be achieved.
AB - Partial inactivation and transient depletion of monocytes/macrophages by liposomal bisphosphonates (LIP-BPs) is widely experimented in various inflammatory disorders including restenosis. Previous studies on activation of cytokines by LIP-BPs are limited to certain cell lines. Moreover, the correlation between in vitro and in vivo studies and complement (C) activation has not been reported. We report here a comprehensive study on the bioactivity of LIP-BPs on various cells' internalization and proliferation, mechanism of cell death, cytokines (in vitro and in vivo) and C activation (in the rat, rabbit and pig). The role of the following parameters has been determined i) drug type (clodronate/alendronate); ii) vesicles size (60-800. nm); iii) charge (neutral/negative/ positive); and iv) cell culture type (various cell lines and primary cultures). It was found that monocyte/macrophage inhibition and cytokine activation depend on the cell type, with a limited correlation to the bioactivity obtained in the rat and rabbit models of restenosis. Negatively charged liposomes (85 ± 20 nm) effectively depleted rabbit's monocytes (67% depletion), with a minor activation of cytokines and no C activation. It is concluded that cell culture studies are insufficient for assessing cytokine activation, and that by controlling LIP-BP properties (size, charge and drug type) optimal bioactivity could be achieved.
KW - Anti-inflammation
KW - Bisphosphonates
KW - Complement activation
KW - Cytokines
KW - Liposomes
KW - Monocytes/macrophages
KW - Restenosis
UR - http://www.scopus.com/inward/record.url?scp=77955416877&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2010.03.011
DO - 10.1016/j.jconrel.2010.03.011
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 20359513
AN - SCOPUS:77955416877
SN - 0168-3659
VL - 146
SP - 182
EP - 195
JO - Journal of Controlled Release
JF - Journal of Controlled Release
IS - 2
ER -